PRESS RELEASE

Q3 2026 — Press release

Q3 2026PDF · 21 pages1.9 MB
For immediate release
Johnson & Johnson reports Q3 2026 results , raises 2026 guidance
• 202 6 Third -Quarter reported sales growth of 5.9% to $ 25.4 Billion with operational growth of 6.0 %* and adjusted operational
growth of 6.1%*
• 202 6 Third -Quarter earnings per share (EPS) of $0.09 reflects a one -time special charge for the proposed talc litigation
resolution , the acquisition of Firefly Bio, Inc. , and the strategic collaboration with Sail Biomedicines; adjusted EPS * of $ 2.59
also reflects the impact of the se M&A deals
• Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101. 2
Billion or 7.4% at the midpoint and increasing adjusted EPS* guidance by $0. 06 to $11.10 or 2.9% at the midpoint
• Significant innovation including the market authorization of OTTAVA as the world’s first table -integrated soft tissue robotic
system, approval of IMAAVY in warm autoimmune hemolytic anemia (wAIHA), and priority review for RYBREVANT FASPRO for
advanced head and neck cancer
New Brunswick, N.J. ( October 13, 202 6) – Johnson & Johnson (NYSE: JNJ) today announced results for third -quarter 2026.
“Johnson & Johnson’s strong third -quarter performance and increased sequential growth reflect the accelerating momentum of
our focused portfolio,” said Joaquin Duato, Chairman and Chief Executive Officer. “In the third quarter, we advanced
breakthroughs th at will redefine care for patients, from delivering on e of our most transformative MedTech innovations with
OTTAVA to reporting positive Phase 3 results in multiple myeloma. This progress, together with strategic investments in high -
growth areas, gives us clearer line of sight to double -digit growth by the en d of the decade.”
Overall financial results
Q3
($ in Millions, except EPS) 2026 2025 % Change
Reported Sales $ 25,399 $ 23,993 5.9 %
Net Earnings $210 $5,152 (95.9 )%
EPS (diluted) $0.09 $2.12 (95.8 )%
Q3
Non -GAAP* ($ in Millions, except EPS) 2026 2025 % Change
Operational Sales 1,2 6.0 %
Adjusted Operational Sales 1,3 6.1%
Adjusted Net Earnings 1,4 $6,339 $6,801 (6.8)%
Adjusted EPS (diluted) 1,4 $2.59 $2.80 (7.5)%
Free Cash Flow 5,6 ~$15,100 $14,226
1 Non-GAAP financial measure; refer to reconciliations of non -GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items
5 Non-GAAP financial measure; defined as cash flow from operating activities , less additions to property, plant and equipment . Cash flow
from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings .
6 Third -quarter YTD 202 6 is estimated as of October 13, 202 6
Media contact:
media-relations@its.jnj.com
Investor contact:
investor -relations@its.jnj.com

-- 1 of 21 --

Note: values may have been rounded
Regional sales results
Q3 % Change
($ in Millions) 2026 202 5 Reported Operational 1,2 Currency
Adjusted
Operational 1,3
U.S. $ 14,959 $ 13,708 9.1% 9.1 - 9.1
International 10,440 10,285 1.5 1.8 (0.3) 1.9
Worldwide $ 25,399 $ 23 ,993 5.9% 6.0 (0.1) 6.1
1 Non-GAAP financial measure; refer to reconciliations of non -GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Segment sales results
Q3 % Change
($ in Millions) 2026 202 5 Reported Operational 1,2 Currency
Adjusted
Operational 1,3
Innovative Medicine $ 16,757 $ 15,563 7.7% 7.9 (0.2 ) 8.0
MedTech 8,642 8,430 2.5 2.5 0.0 2.5
Worldwide $ 25,3 99 $ 23,993 5.9 % 6.0 (0.1) 6.1
1 Non-GAAP financial measure; refer to reconciliations of non -GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Third -Quarter 202 6 segment commentary:
Operational sales* reflected below excludes the impact of translational currency.
Innovative Medicine
Innovative Medicine worldwide operational sales grew 7.9%*, with divestitures negatively impacting growth by 10 basis points.
Growth was primarily driven by TREMFYA and new product s within Other in Immunology, DARZALEX, CARVYKTI, TECVAYLI ,
RYBREVANT/LAZCLUZE , and ERLEADA in Oncology , and SPRAVATO and CAPLYTA in Neuroscience . Growth was partially offset
by STELARA ( an approximate 690 basis points impact ), SIMPONI/SIMPONI ARIA , and REMICADE in Immunology , as well as
OPSUMIT/OPSYNVI in Pulmonary Hypertension, and IMBRUVICA in Oncology .
MedTech
MedTech worldwide operational sales grew 2.5%*. Growth was primarily driven by electrophysiology products and Shockwave in
Cardiovascular , contact lenses in Vision , as well as trauma in Orthop aedics.

-- 2 of 21 --

Full-year 202 6 guidance:
Johnson & Johnson does not provide GAAP financial measures on a forward -looking basis because the company is unable to
predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition -related
expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on
various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
($ in Billions, except EPS) October 2026 July 29 , 2026
Adjusted Operational Sales 1,2
Change vs. Prior Year / Mid -point 6.4% – 6.8% / 6.6% 6.2% – 6.8% / 6.5%
Operational Sales 2 / Mid-point
Change vs. Prior Year / Mid -point
$100.5B – $100.9B /$100.7B
6.7% – 7.1% / 6.9%
$100.3B – $100.9B / $100.6B
6.5% – 7.1% / 6.8%
Estimated Reported Sales 3/ Mid-point
Change vs. Prior Year / Mid -point
$101.0B – $101.4B / $101.2B
7.2% – 7.6% / 7.4%
$100.8B – $101.4B / $101.1B
7.0% – 7.6% / 7.3%
Adjusted Operational EPS (Diluted) 2,4 / Mid-point
Change vs. Prior Year / Mid -point
$10.95 – $11.05 / $11.00
1.5% – 2.4% / 2.0%
$10.86 – $11.01 / $10.94
0.7% – 2.1% / 1.4%
Adjusted EPS (Diluted) 3,4 / Mid-point
Change vs. Prior Year / Mid -point
$11.05 – $11.15 / $11.10
2.4% – 3.3% / 2.9%
$10.96 – $11.11 / $11.04
1.6% – 3.0% / 2.3%
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: October 2026 = $ 1.15and July 202 6 = $ 1.15 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
Note: percentages may have been rounded
Other modeling considerations will be provided on the webcast .
Notable announcements in the quarter:
The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the
Securities and Exchange Commission, including its Current Reports on Form 8 -K, Quarterly Reports on Form 10 -Q and Annual
Reports on Form 10 -K. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson &
Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations
section of the company’s website at Investor News , as well as Innovative Medicine Newsroom , MedTech News & Events , and
www.factsabouttalc.com .
Regulatory Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX
Reusable Contact Lense s1 Press Release
FDA approves IMAAVY® (nipocalimab -aahu) as first -ever treatment for
warm autoimmune hemolytic anemia (wAIHA), representing a landmark
advancement for patients
Press Release
Johnson & Johnson's RYBREVANT FASPRO ™ (amivantamab and
hyaluronidase -lpuj) receives U.S. FDA Priority Review as potential first -
in-class EGFR - and MET -targeted subcutaneous treatment for advanced
head and neck cancer
Press Release
Johnson & Johnson Receives FDA Market Authorization in the U.S. for
its OTTAVA ™ Robotic Surgical System Press Release
Johnson & Johnson Announces MONARCH ™ QUEST 3, Advancing the
Latest in Robotically -Assisted Bronchoscopy Press Release
Data Releases
New Johnson & Johnson ICOTYDE® (icotrokinra) long -term data
demonstrate robust 2 - year results in the treatment of adults and
adolescents with plaque psoriasis 1
Press Release

-- 3 of 21 --

Johnson & Johnson announces new ICOTYDE ™ (icotrokinra) data in
difficult -to-treat plaque psoriasis with proven durability through 2 -
years, affirming its use as a powerful first line systemic therapy 1
Press Release
Johnson & Johnson presents new data reinforcing sustained disease
control and improved daily function achieved with IMAAVY®
(nipocalimab -aahu) in generalized myasthenia gravis (gMG)
Press Release
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and
only IL-23 inhibitor to show significant improvement in spinal pain and
stiffness in landmark axial psoriatic arthritis (PsA) study
Press Release
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered
five -year treatment -free remissions in 50% of patients in early line
relapsed/refractory multiple myeloma
Press Release
New model -based analysis further supports the potential of TECVAYLI®
(teclistamab -cqyv) plus DARZALEX FASPRO® (daratumumab and
hyaluronidase -hj) to redene long -term survival expectations in early line
relapsed/refractory multiple myeloma
Press Release
CAPLYTA® (lumateperone) shows s ignificant and rapid improvement in
bipolar mania in pivotal Phase 3 study Press Release
RYBREVANT FASPRO ™ (amivantamab and hyaluronidase -lpuj) plus
LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of
treatment -related events at WCLC 2026
Press Release
Johnson & Johnson's RYBREVANT® (amivantamab -vmjw) plus
chemotherapy delivers longest reported median overall survival in EGFR
exon 20 insertion mutation -positive lung cancer
Press Release
Johnson & Johnson spotlights new neuropsychiatry data across bipolar
mania, depression and schizophrenia at Psych Congress 2026 Press Release
TECVAYLI® + TALVEY® reduced the risk of disease progression or death
by 89% and the risk of death by 62% in earlier -line relapsed/refractory
multiple myeloma
Press Release
Other New Global Survey by Johnson & Johnson Finds Most Women Don’t
Connect Eye Health Changes with Menopause 1 Press Release
Johnson & Johnson’s Executive Vice President Jennifer Taubert to
Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative
Medicine Effective September
Press Release
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to
Advance Next -Generation Oncology Innovation Press Release
Johnson & Johnson Announces Collaboration with Sail Biomedicines to
Advance in vivo CAR -T Programs and Transform Autoimmune Disease
Through Immune Reset
Press Release
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc
Litigation Press Release
1 Subsequent to the quarter
Webcast information:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8: 30 a.m., Eastern
Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson &
Johnson website . A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations
section of the company's website at events -and-presentations .
About Johnson & Johnson:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world
where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are
personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full

-- 4 of 21 --

spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at www.jnj.com.
Non-GAAP financial measures:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding th e
net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted
ear nings per share” and “adjusted operational diluted earnings per share” excluding after -tax intangible amortization expense
and special items, are non -GAAP financial measures and should not be considered replacements for, and should be read
together with, t he most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non -
GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial
schedules of the earnings rele ase and the Investor Relations section of the company's website at quarterly results .
Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly
results . These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of
non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including
adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and
a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at
quarterly results .
Note to investors concerning forward -looking statements:
This press release contains “forward -looking statements” as defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things: future operating and financial performance, product development, and market position and
business str ategy. The reader is cautioned not to rely on these forward -looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties
materialize, actual r esults could vary materially from the expectations and projections of Johnson & Johnson. Risks and
uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuation s or
changes to applicable laws and regulations; competition, including technological advances, new products and patents attained
by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and
obtaining regulatory approvals; unc ertainty of commercial success for new and existing products; challenges to patents; the
impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring pla ns;
the impact of business combinations an d divestitures; manufacturing difficulties or delays, internally or within the supply chain;
product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or
government action, including related to pr oduct liability claims; changes to applicable laws and regulations, including tax laws
and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of
purchasers of health care products and services; financial instability of international economies and legal systems and
sovereign risk; increased scrutiny of the health care industry by government agencies ; and the Company's ability to
successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation .
A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most rece nt
Annual Report on Form 10 -K, including in the sections captioned “Cautionary Note Regarding Forward -Looking Statements” and
“Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10 -Q and other filings with the
Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com, investor.jnj.com ,
or on request from Johnson & Johnson. Any forward -looking statement made in this release speaks only as of the date of this
release. Johnson & Johnson does not undertake to update any forward -looking statement as a result of new information or
future eve nts or developments.

-- 5 of 21 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2026 2025 Total Operations Currency 2026 2025 Total Operations Currency
Sales to customers by
segment of business
Innovative Medicine
U.S. 10,447	$ 9,402 11.1 % 11.1 - 29,297	$ 26,655 9.9 % 9.9 -
International 6,310 6,161 2.4 3.0 (0.6) 19,270 17,983 7.2 3.6 3.6
16,757 15,563 7.7 7.9 (0.2) 48,567 44,638 8.8 7.4 1.4
MedTech
U.S. 4,512 4,306 4.8 4.8 - 13,525 12,902 4.8 4.8 -
International 4,130 4,124 0.1 0.1 0.0 12,679 12,089 4.9 2.2 2.7
8,642 8,430 2.5 2.5 0.0 26,204 24,991 4.9 3.5 1.4
U.S. 14,959 13,708 9.1 9.1 - 42,822 39,557 8.3 8.3 -
International 10,440 10,285 1.5 1.8 (0.3) 31,949 30,072 6.2 3.0 3.2
Worldwide 25,399	$ 23,993 5.9 % 6.0 (0.1) 74,771	$ 69,629 7.4 % 6.0 1.4
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
THIRD QUARTER NINE MONTHS
Percent Change

-- 6 of 21 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2026 2025 Total Operational Currency 2026 2025 Total Operational Currency
Sales to customers by
geographic area
U.S. 14,959	$ 13,708 9.1 % 9.1 - 42,822	$ 39,557 8.3 % 8.3 -
Europe 5,405 5,440 (0.6) 1.0 (1.6) 16,979 15,937 6.5 2.3 4.2
Western Hemisphere excluding U.S. 1,385 1,231 12.5 8.0 4.5 3,987 3,604 10.6 4.5 6.1
Asia-Pacific, Africa 3,650 3,614 1.0 1.0 0.0 10,983 10,531 4.3 3.6 0.7
International 10,440 10,285 1.5 1.8 (0.3) 31,949 30,072 6.2 3.0 3.2
Worldwide 25,399	$ 23,993 5.9 % 6.0 (0.1) 74,771	$ 69,629 7.4 % 6.0 1.4
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
THIRD QUARTER NINE MONTHS
Percent Change

-- 7 of 21 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 25,399	$ 100.0 23,993	$ 100.0 5.9
Cost of products sold 8,097 31.9 7,303 30.4 10.9
Gross Profit 17,302 68.1 16,690 69.6 3.7
Selling, marketing and administrative expenses 6,285 24.7 5,922 24.7 6.1
Research and development expense 4,652 18.3 3,672 15.3 26.7
In-process research and development impairments 339 1.4 - -
Interest (income) expense, net 31 0.1 18 0.1
Other (income) expense, net 5,780 22.8 (478) (2.0)
Restructuring 181 0.7 63 0.3
Earnings before provision for taxes on income 34 0.1 7,493 31.2 (99.5)
(Benefit from)/Provision for taxes on income (176) (0.7) 2,341 9.7 (107.5)
Net earnings 210	$ 0.8 5,152	$ 21.5 (95.9)
Net earnings per share (Diluted) 0.09	$ 2.12	$ (95.8)
Average shares outstanding (Diluted) 2,448.6 2,428.6
Effective tax rate (517.6) % 31.2 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 7,672	$ 30.2 8,436	$ 35.2 (9.1)
Net earnings 6,339	$ 25.0 6,801	$ 28.3 (6.8)
Net earnings per share (Diluted) 2.59	$ 2.80	$ (7.5)
Effective tax rate 17.4 % 19.4 %
(1) See Reconciliation of Non-GAAP Financial Measures.
THIRD QUARTER
2026 2025

-- 8 of 21 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 74,771	$ 100.0 69,629	$ 100.0 7.4
Cost of products sold 24,254 32.4 22,288 32.0 8.8
Gross Profit 50,517 67.6 47,341 68.0 6.7
Selling, marketing and administrative expenses 18,751 25.1 16,923 24.3 10.8
Research and development expense 11,832 15.8 10,413 15.0 13.6
In-process research and development impairments 375 0.5 - -
Interest (income) expense, net 136 0.2 (62) (0.1)
Other (income) expense, net 6,405 8.6 (7,692) (11.1)
Restructuring 247 0.3 144 0.2
Earnings before provision for taxes on income 12,771 17.1 27,615 39.7 (53.8)
Provision for taxes on income 1,792 2.4 5,927 8.6 (69.8)
Net earnings 10,979	$ 14.7 21,688	$ 31.1 (49.4)
Net earnings per share (Diluted) 4.49	$ 8.94	$ (49.8)
Average shares outstanding (Diluted) 2,445.8 2,424.8
Effective tax rate 14.0 % 21.5 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 24,153	$ 32.3 24,635	$ 35.4 (2.0)
Net earnings 20,034	$ 26.8 20,206	$ 29.0 (0.9)
Net earnings per share (Diluted) 8.19	$ 8.33	$ (1.7)
Effective tax rate 17.1 % 18.0 %
(1) See Reconciliation of Non-GAAP Financial Measures.
NINE MONTHS
2026 2025

-- 9 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2026 2025 2026 2025
Net Earnings, after tax- as reported $210 $5,152 $10,979 $21,688
Pre-tax Adjustments
Litigation related 5,519 15 6,116 (6,894)
Intangible Asset Amortization expense 1,240 1,048 3,732 3,435
Restructuring related 1 195 168 533 302
Orthopaedics separation related 369 - 746 -
Acquisition, integration and divestiture related (34) 97 142 475
(Gains)/losses on securities 10 (387) (262) (327)
IPR&D impairments 339 - 375 -
Other - 2 - 29
Tax Adjustments
Tax impact on special item adjustments 2 (1,677) (168) (2,469) 826
Tax legislation and other tax related 168 874 142 672
Adjusted Net Earnings , after tax $6,339 $6,801 $20,034 $20,206
Average shares outstanding (Diluted) 2,448.6 2,428.6 2,445.8 2,424.8
Adjusted net earnings per share (Diluted) $2.59 $2.80 $8.19 $8.33
Operational adjusted net earnings per share (Diluted) $2.61 $8.04
Notes:
1
2
Third Quarter Nine Months Ended
In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline
operations. The program is expected to be substantially completed by the end of fiscal year 2029 with estimated costs between $650 - $750 million, and include site and supplier exit costs, decommissioning and asset impairment
costs. Restructuring expenses of $74 million in the fiscal third quarter of 2026 ($274 million Q3 2026 YTD), were primarily related to asset impairments and exit costs.
In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the
network. Restructuring expenses of $80 million were recorded in the fiscal third quarter of 2026 ($194 million Q3 2026 YTD) and $128 million in the fiscal third quarter of 2025 ($157 million Q3 2025 YTD) primarily includes costs
related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.
In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements.
The restructuring expenses of $41 million in the fiscal third quarter of 2026 ($65 million Q3 2026 YTD) and $40 million in the fiscal third quarter of 2025 ($145 million Q3 2025 YTD) includes costs related to market and product
exits. This program will be completed as of Q4 2026 at a total cost of approximately $1 billion.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

-- 10 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 7.7% 2.5% 5.9%
U.S. 11.1% 4.8% 9.1%
International 2.4% 0.1% 1.5%
WW Currency (0.2) 0.0 (0.1)
U.S. - - -
International (0.6) 0.0 (0.3)
WW Operational 7.9% 2.5% 6.0%
U.S. 11.1% 4.8% 9.1%
International 3.0% 0.1% 1.8%
All Other Acquisitions and Divestitures (A&D) 0.1 0.0 0.1
U.S. 0.0 0.0 0.0
International 0.2 0.0 0.1
WW Adjusted Operational Ex A&D 8.0% 2.5% 6.1%
U.S. 11.1% 4.8% 9.1%
International 3.2% 0.1% 1.9%
Adjusted Operational Sales Growth
THIRD QUARTER 2026 ACTUAL vs. 2025 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 11 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 8.8% 4.9% 7.4%
U.S. 9.9% 4.8% 8.3%
International 7.2% 4.9% 6.2%
WW Currency 1.4 1.4 1.4
U.S. - - -
International 3.6 2.7 3.2
WW Operational 7.4% 3.5% 6.0%
U.S. 9.9% 4.8% 8.3%
International 3.6% 2.2% 3.0%
Caplyta (0.6) (0.4)
U.S. (1.0) (0.7)
International 0.0 0.0
All Other Acquisitions and Divestitures (A&D) 0.1 0.1 0.1
U.S. 0.0 0.1 0.0
International 0.2 0.0 0.1
WW Adjusted Operational Ex A&D 6.9% 3.6% 5.7%
U.S. 8.9% 4.9% 7.6%
International 3.8% 2.2% 3.1%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
NINE MONTHS 2026 ACTUAL vs. 2025 ACTUAL
Segments

-- 12 of 21 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
INNOVATIVE MEDICINE SEGMENT (2) 2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
ONCOLOGY
US 4,267	$ 3,468 23.0% 23.0% - 11,951	$ 9,866 21.1% 21.1% -
Intl 3,335 3,060 9.0% 9.5% (0.5)% 10,030 8,652 15.9% 11.9% 4.0%
WW 7,602 6,529 16.4% 16.7% (0.3)% 21,981 18,519 18.7% 16.8% 1.9%
DARZALEX
US 2,528 2,088 21.1% 21.1% - 7,171 5,934 20.9% 20.9% -
Intl 1,711 1,584 8.0% 8.5% (0.5)% 5,239 4,514 16.1% 11.9% 4.2%
WW 4,239 3,672 15.4% 15.6% (0.2)% 12,410 10,448 18.8% 17.0% 1.8%
CARVYKTI
US 472 396 19.4% 19.4% - 1,377 1,072 28.5% 28.5% -
Intl 238 128 85.3% 84.1% 1.2% 587 260 * * *
WW 710 524 35.5% 35.2% 0.3% 1,964 1,332 47.4% 45.5% 1.9%
TECVAYLI
US 236 115 * * - 549 334 64.4% 64.4% -
Intl 77 62 24.0% 25.9% (1.9)% 225 160 40.6% 37.7% 2.9%
WW 312 177 76.6% 77.3% (0.7)% 774 494 56.7% 55.7% 1.0%
TALVEY
US 112 85 31.6% 31.6% - 325 235 38.1% 38.1% -
Intl 59 37 62.9% 66.9% (4.0)% 172 79 * * *
WW 171 122 40.9% 42.1% (1.2)% 497 314 58.3% 57.5% 0.8%
RYBREVANT / LAZCLUZE
US 201 136 47.9% 47.9% - 566 388 46.1% 46.1% -
Intl 119 61 94.5% 98.3% (3.8)% 300 130 * * *
WW 320 198 62.3% 63.5% (1.2)% 866 518 67.4% 67.5% (0.1)%
ERLEADA
US 423 378 11.8% 11.8% - 1,161 1,048 10.8% 10.8% -
Intl 600 558 7.7% 7.7% 0.0% 1,806 1,567 15.3% 10.8% 4.5%
WW 1,023 936 9.4% 9.4% 0.0% 2,967 2,615 13.5% 10.8% 2.7%
IMBRUVICA
US 145 211 (31.6)% (31.6)% - 437 685 (36.3)% (36.3)% -
Intl 420 483 (13.2)% (12.6)% (0.6)% 1,386 1,453 (4.7)% (8.7)% 4.0%
WW 563 695 (18.8)% (18.4)% (0.4)% 1,822 2,139 (14.8)% (17.5)% 2.7%
OTHER ONCOLOGY (3)
US 149 61 * * - 365 171 * * -
Intl 111 147 (24.4)% (23.9)% (0.5)% 314 488 (35.7)% (36.0)% 0.3%
WW 262 207 26.3% 26.7% (0.4)% 680 659 3.2% 2.9% 0.3%
See footnotes at end of schedule
% Change	% Change

-- 13 of 21 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
IMMUNOLOGY
US 2,804	$ 2,676 4.8% 4.8% - 7,031	$ 7,377 (4.7)% (4.7)% -
Intl 1,417 1,493 (5.1)% (4.8)% (0.3)% 4,414 4,492 (1.7)% (4.9)% 3.2%
WW 4,221 4,168 1.3% 1.4% (0.1)% 11,445 11,868 (3.6)% (4.8)% 1.2%
TREMFYA
US 1,772 989 79.1% 79.1% - 4,279 2,384 79.5% 79.5% -
Intl 624 434 43.7% 43.4% 0.3% 1,771 1,181 49.9% 44.7% 5.2%
WW 2,396 1,424 68.3% 68.2% 0.1% 6,050 3,566 69.7% 67.9% 1.8%
SIMPONI / SIMPONI ARIA
US 269 309 (13.2)% (13.2)% - 798 906 (11.9)% (11.9)% -
Intl 299 377 (20.6)% (20.3)% (0.3)% 1,035 1,130 (8.4)% (11.4)% 3.0%
WW 568 687 (17.3)% (17.1)% (0.2)% 1,833 2,036 (10.0)% (11.6)% 1.6%
REMICADE
US 258 326 (20.8)% (20.8)% - 742 923 (19.6)% (19.6)% -
US Exports (4) 12 19 (37.1)% (37.1)% - 40 63 (36.6)% (36.6)% -
Intl 124 132 (6.2)% (7.5)% 1.3% 372 413 (9.8)% (12.9)% 3.1%
WW 394 476 (17.3)% (17.6)% 0.3% 1,154 1,398 (17.5)% (18.4)% 0.9%
STELARA
US 368 1,022 (64.0)% (64.0)% - 924 3,081 (70.0)% (70.0)% -
Intl 349 549 (36.5)% (35.5)% (1.0)% 1,188 1,768 (32.8)% (34.9)% 2.1%
WW 716 1,570 (54.4)% (54.0)% (0.4)% 2,112 4,848 (56.4)% (57.2)% 0.8%
OTHER IMMUNOLOGY
US 126 12 * * - 249 21 * * -
Intl 21 0 * * * 48 0 * * *
WW 147 12 * * * 297 21 * * *
NEUROSCIENCE
US 1,733 1,367 26.8% 26.8% - 4,886 3,712 31.6% 31.6% -
Intl 642 658 (2.4)% (1.7)% (0.7)% 2,001 2,011 (0.5)% (3.0)% 2.5%
WW 2,375 2,024 17.3% 17.6% (0.3)% 6,887 5,722 20.3% 19.5% 0.8%
SPRAVATO
US 559 405 37.9% 37.9% - 1,479 1,047 41.3% 41.3% -
Intl 66 53 22.7% 21.4% 1.3% 197 146 34.8% 28.1% 6.7%
WW 624 459 36.1% 36.0% 0.1% 1,676 1,193 40.5% 39.7% 0.8%
CAPLYTA (5)
US 398 240 66.1% 66.1% - 1,029 451 * * -
Intl - - - - - - - - - -
WW 398 240 66.1% 66.1% - 1,029 451 * * -
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 739 664 11.4% 11.4% - 2,235 2,021 10.6% 10.6% -
Intl 258 267 (3.0)% (2.4)% (0.6)% 816 804 1.5% (0.8)% 2.3%
WW 998 929 7.3% 7.5% (0.2)% 3,051 2,824 8.0% 7.4% 0.6%
CONCERTA / Methylphenidate
US 6 14 (56.3)% (56.3)% - 40 76 (47.3)% (47.3)% -
Intl 138 127 8.1% 8.9% (0.8)% 386 376 2.4% 1.1% 1.3%
WW 143 140 2.1% 2.9% (0.8)% 425 452 (5.9)% (7.0)% 1.1%
OTHER NEUROSCIENCE
US 32 46 (30.6)% (30.6)% - 104 119 (12.6)% (12.6)% -
Intl 180 210 (14.3)% (13.1)% (1.2)% 602 684 (12.0)% (14.5)% 2.5%
WW 212 256 (17.3)% (16.2)% (1.1)% 706 803 (12.1)% (14.2)% 2.1%
See footnotes at end of schedule
% Change	% Change

-- 14 of 21 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
PULMONARY HYPERTENSION (PH)
US 588	$ 815 (27.8)% (27.8)% - 2,233	$ 2,358 (5.3)% (5.3)% -
Intl 309 300 2.9% 4.1% (1.2)% 942 895 5.2% 2.9% 2.3%
WW 897 1,115 (19.5)% (19.2)% (0.3)% 3,175 3,253 (2.4)% (3.0)% 0.6%
UPTRAVI
US 383 392 (2.2)% (2.2)% - 1,154 1,139 1.3% 1.3% -
Intl 100 92 8.9% 8.4% 0.5% 306 272 12.7% 7.9% 4.8%
WW 483 484 (0.1)% (0.2)% 0.1% 1,460 1,411 3.5% 2.6% 0.9%
OPSUMIT / OPSYNVI
US 193 409 (52.8)% (52.8)% - 1,042 1,175 (11.3)% (11.3)% -
Intl 179 168 5.9% 7.8% (1.9)% 538 507 6.0% 4.4% 1.6%
WW 372 578 (35.7)% (35.2)% (0.5)% 1,580 1,682 (6.1)% (6.6)% 0.5%
OTHER PULMONARY HYPERTENSION
US 12 13 (7.3)% (7.3)% - 37 44 (15.5)% (15.5)% -
Intl 30 39 (23.8)% (21.2)% (2.6)% 98 116 (15.6)% (15.3)% (0.3)%
WW 42 53 (19.7)% (17.7)% (2.0)% 135 160 (15.6)% (15.4)% (0.2)%
INFECTIOUS DISEASES (ID)
US 317 326 (2.7)% (2.7)% - 959 961 (0.2)% (0.2)% -
Intl 496 501 (1.2)% (0.1)% (1.1)% 1,506 1,472 2.3% (1.7)% 4.0%
WW 813 829 (1.8)% (1.1)% (0.7)% 2,465 2,434 1.3% (1.1)% 2.4%
EDURANT / rilpivirine
US 5 7 (31.6)% (31.6)% - 15 21 (30.1)% (30.1)% -
Intl 382 378 1.0% 2.4% (1.4)% 1,131 1,082 4.5% 0.6% 3.9%
WW 386 385 0.4% 1.8% (1.4)% 1,145 1,103 3.8% 0.0% 3.8%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 307 315 (2.5)% (2.5)% - 937 932 0.6% 0.6% -
Intl 74 81 (8.9)% (7.7)% (1.2)% 259 264 (1.9)% (6.2)% 4.3%
WW 381 397 (3.8)% (3.6)% (0.2)% 1,196 1,196 0.0% (0.9)% 0.9%
OTHER INFECTIOUS DISEASES
US 5 4 29.9% 29.9% - 7 8 (11.4)% (11.4)% -
Intl 40 42 (6.2)% (7.9)% 1.7% 116 126 (8.0)% (11.7)% 3.7%
WW 46 47 (3.0)% (4.5)% 1.5% 124 135 (8.2)% (11.7)% 3.5%
CARDIOVASCULAR / METABOLISM / OTHER (CVM)
US 736 750 (1.9)% (1.9)% - 2,235 2,381 (6.1)% (6.1)% -
Intl 112 149 (24.3)% (23.8)% (0.5)% 378 461 (17.9)% (20.9)% 3.0%
WW 849 899 (5.6)% (5.5)% (0.1)% 2,614 2,842 (8.0)% (8.5)% 0.5%
XARELTO
US 653 635 2.7% 2.7% - 1,959 1,946 0.7% 0.7% -
Intl - - - - - - - - - -
WW 653 635 2.7% 2.7% - 1,959 1,946 0.7% 0.7% -
OTHER
US 84 115 (27.2)% (27.2)% - 276 435 (36.5)% (36.5)% -
Intl 112 149 (24.3)% (23.8)% (0.5)% 378 461 (17.9)% (20.9)% 3.0%
WW 197 264 (25.5)% (25.3)% (0.2)% 655 896 (26.9)% (28.5)% 1.6%
TOTAL PH, ID, CVM
US 1,643 1,891 (13.2)% (13.2)% - 5,428 5,700 (4.8)% (4.8)% -
Intl 917 950 (3.5)% (2.5)% (1.0)% 2,826 2,828 (0.1)% (3.4)% 3.3%
WW 2,560 2,843 (9.9)% (9.6)% (0.3)% 8,254 8,529 (3.2)% (4.3)% 1.1%
TOTAL INNOVATIVE MEDICINE
US 10,447 9,402 11.1% 11.1% - 29,297 26,655 9.9% 9.9% -
Intl 6,310 6,161 2.4% 3.0% (0.6)% 19,270 17,983 7.2% 3.6% 3.6%
WW 16,757	$ 15,563 7.7% 7.9% (0.2)% 48,567	$ 44,638 8.8% 7.4% 1.4%
See footnotes at end of schedule
% Change	% Change

-- 15 of 21 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
MEDTECH SEGMENT (2) 2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
CARDIOVASCULAR
US 1,397	$ 1,306 7.0% 7.0% - 4,222	$ 3,931 7.4% 7.4% -
Intl 910 908 0.2% (0.2)% 0.4% 2,866 2,698 6.2% 3.4% 2.8%
WW 2,307 2,213 4.3% 4.1% 0.2% 7,088 6,629 6.9% 5.8% 1.1%
ELECTROPHYSIOLOGY
US 771 720 7.0% 7.0% - 2,290 2,145 6.8% 6.8% -
Intl 717 698 2.8% 1.8% 1.0% 2,219 2,064 7.5% 4.3% 3.2%
WW 1,487 1,418 4.9% 4.4% 0.5% 4,509 4,209 7.1% 5.6% 1.5%
ABIOMED
US 335 336 (0.3)% (0.3)% - 1,066 1,035 3.0% 3.0% -
Intl 78 86 (10.4)% (6.5)% (3.9)% 275 256 7.2% 5.4% 1.8%
WW 412 423 (2.3)% (1.5)% (0.8)% 1,340 1,291 3.8% 3.5% 0.3%
SHOCKWAVE
US 261 220 18.8% 18.8% - 771 659 17.0% 17.0% -
Intl 64 59 9.3% 11.2% (1.9)% 194 169 14.8% 15.1% (0.3)%
WW 325 278 16.8% 17.2% (0.4)% 965 828 16.6% 16.6% 0.0%
OTHER CARDIOVASCULAR
US 31 30 3.6% 3.6% - 96 93 3.2% 3.2% -
Intl 50 65 (21.9)% (23.1)% 1.2% 177 209 (15.0)% (17.7)% 2.7%
WW 81 95 (13.9)% (14.7)% 0.8% 273 302 (9.4)% (11.3)% 1.9%
SURGERY
US 1,070 1,031 3.7% 3.7% - 3,210 3,076 4.3% 4.3% -
Intl 1,459 1,511 (3.4)% (4.2)% 0.8% 4,483 4,417 1.5% (1.6)% 3.1%
WW 2,528 2,542 (0.6)% (1.0)% 0.4% 7,692 7,493 2.7% 0.8% 1.9%
ADVANCED
US 500 477 5.1% 5.1% - 1,476 1,411 4.7% 4.7% -
Intl 654 688 (5.0)% (5.7)% 0.7% 1,991 1,991 0.0% (2.9)% 2.9%
WW 1,155 1,165 (0.9)% (1.3)% 0.4% 3,467 3,402 1.9% 0.2% 1.7%
GENERAL
US 568 555 2.4% 2.4% - 1,733 1,666 4.0% 4.0% -
Intl 805 823 (2.2)% (3.0)% 0.8% 2,492 2,426 2.7% (0.6)% 3.3%
WW 1,373 1,378 (0.3)% (0.8)% 0.5% 4,225 4,092 3.3% 1.3% 2.0%
See footnotes at end of schedule
% Change	% Change

-- 16 of 21 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
VISION
US 596	$ 571 4.3% 4.3% - 1,740	$ 1,694 2.7% 2.7% -
Intl 865 828 4.4% 5.6% (1.2)% 2,537 2,354 7.8% 6.3% 1.5%
WW 1,461 1,400 4.4% 5.1% (0.7)% 4,277 4,048 5.6% 4.8% 0.8%
CONTACT LENSES / OTHER
US 465 456 1.9% 1.9% - 1,378 1,337 3.1% 3.1% -
Intl 588 562 4.7% 6.2% (1.5)% 1,669 1,565 6.6% 5.5% 1.1%
WW 1,053 1,018 3.5% 4.3% (0.8)% 3,047 2,902 5.0% 4.4% 0.6%
SURGICAL
US 132 116 13.6% 13.6% - 363 358 1.4% 1.4% -
Intl 276 266 3.8% 4.3% (0.5)% 867 789 10.0% 8.0% 2.0%
WW 408 383 6.8% 7.1% (0.3)% 1,230 1,147 7.3% 5.9% 1.4%
ORTHOPAEDICS
US 1,448 1,396 3.8% 3.8% - 4,353 4,200 3.6% 3.6% -
Intl 898 878 2.2% 2.9% (0.7)% 2,794 2,620 6.6% 3.5% 3.1%
WW 2,345 2,274 3.2% 3.4% (0.2)% 7,146 6,820 4.8% 3.6% 1.2%
HIPS
US 271 262 3.5% 3.5% - 831 796 4.4% 4.4% -
Intl 148 144 2.6% 3.0% (0.4)% 465 440 5.7% 2.1% 3.6%
WW 419 405 3.1% 3.3% (0.2)% 1,296 1,235 4.9% 3.6% 1.3%
KNEES
US 221 216 2.1% 2.1% - 688 673 2.2% 2.2% -
Intl 165 160 3.0% 4.4% (1.4)% 528 482 9.7% 7.1% 2.6%
WW 386 377 2.5% 3.1% (0.6)% 1,216 1,155 5.3% 4.2% 1.1%
TRAUMA
US 555 512 8.6% 8.6% - 1,623 1,515 7.1% 7.1% -
Intl 288 281 2.4% 2.8% (0.4)% 880 818 7.6% 4.4% 3.2%
WW 844 793 6.4% 6.5% (0.1)% 2,504 2,333 7.3% 6.2% 1.1%
SPINE, SPORTS & OTHER
US 401 406 (1.2)% (1.2)% - 1,211 1,216 (0.4)% (0.4)% -
Intl 296 293 1.3% 2.0% (0.7)% 920 881 4.5% 1.5% 3.0%
WW 697 698 (0.1)% 0.1% (0.2)% 2,131 2,096 1.7% 0.4% 1.3%
TOTAL MEDTECH
US 4,512 4,306 4.8% 4.8% - 13,525 12,902 4.8% 4.8% -
Intl 4,130 4,124 0.1% 0.1% 0.0% 12,679 12,089 4.9% 2.2% 2.7%
WW 8,642	$ 8,430 2.5% 2.5% 0.0% 26,204	$ 24,991 4.9% 3.5% 1.4%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Includes the sales of ZYTIGA which were previously disclosed separately
(4) Reported as U.S. sales
(5) Acquired with Intra-Cellular Therapies on April 2, 2025
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely
% Change	% Change

-- 17 of 21 --

Innovative Medicine
Third Quarter
September 27,
2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related
Third Quarter
September 27,
2026
Non-GAAP
Cost of products sold 4,486	$ (762) 18 (2) 3,740
Selling, marketing and admin expenses 3,035 3,035
Research and development expense 3,888 3,888
Other segment items 282 24 (92) (53) 4 165
Adjusted Income Before Tax by Segment 5,066 762 (24) - 74 55 (4) - - 5,929
MedTech
Third Quarter
September 27,
2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related
Third Quarter
September 27,
2026
Non-GAAP
Cost of products sold 3,597	$ (478) (13) (6) 3,100
Selling, marketing and admin expenses 3,014 (38) 2,976
Research and development expense 764 (5) 759
Other segment items 491 22 (339) (108) 95 (14) (320) (173)
Adjusted Income Before Tax by Segment 776 478 (22) 339 121 (95) 14 369 - 1,980
Expenses not allocated to segments
Third Quarter
September 27,
2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related
Third Quarter
September 27,
2026
Non-GAAP
Cost of products sold 14	$ 14
Selling, marketing and admin expenses 236 236
Research and development expense - -
Other segment items 5,558 (5,565) (6) (13)
Adjusted Income Before Tax by Segment (5,808) - 5,565 - - 6 - - - (237)
Johnson & Johnson Consolidated
Third Quarter
September 27,
2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related
Third Quarter
September 27,
2026
Non-GAAP
Cost of products sold 8,097	$ (1,240) 5 (2) (6) 6,854
Selling, marketing and admin expenses 6,285 (38) 6,247
Research and development expense 4,652 (5) 4,647
Other (Income) / Expense 5,780 (5,519) (19) 36 (10) (320) (52)
In-process research and development impairments 339 (339) -
Interest (Income)/Expense 31 31
Restructuring 181 (181) -
Adjusted Income Before Tax 34 1,240 5,519 339 195 (34) 10 369 - 7,672
(Benefit from)/Provision for taxes on income (176) 239 1,230 85 37 18 - 68 (168) 1,333
Net Earnings 210 1,001 4,289 254 158 (52) 10 301 168 6,339
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date

-- 18 of 21 --

Innovative Medicine
Third Quarter
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Third Quarter
Sept 28, 2025
Non-GAAP
Cost of products sold 3,672	$ (568) (11) 3,093
Selling, marketing and admin expenses 2,869 2,869
Research and development expense 2,944 2,944
Other segment items (368) 5 (48) 174 (1) (238)
Adjusted Income Before Tax by Segment 6,446 568 (5) - 59 (174) - 1 6,895
MedTech
Third Quarter
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Third Quarter
Sept 28, 2025
Non-GAAP
Cost of products sold 3,612	$ (480) (12) (1) 3,119
Selling, marketing and admin expenses 2,801 2,801
Research and development expense 728 728
Other segment items 2 5 (156) (48) 213 (1) 15
Adjusted Income Before Tax by Segment 1,287 480 (5) 168 49 (213) - 1 1,767
Expenses not allocated to segments
Third Quarter
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Third Quarter
Sept 28, 2025
Non-GAAP
Cost of products sold 19	$ 19
Selling, marketing and admin expenses 252 252
Research and development expense - -
Other segment items (31) (25) 11 (45)
Adjusted Income Before Tax by Segment (240) - 25 - (11) - - - (226)
Johnson & Johnson Consolidated
Third Quarter
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Third Quarter
Sept 28, 2025
Non-GAAP
Cost of products sold 7,303	$ (1,048) (12) (12) 6,231
Selling, marketing and admin expenses 5,922 5,922
Research and development expense 3,672 3,672
Other (Income) / Expense (478) (15) (93) (85) 387 (2) (286)
In-process research and development impairments - -
Interest (Income)/Expense 18 18
Restructuring 63 (63) -
Adjusted Income Before Tax 7,493 1,048 15 168 97 (387) - 2 8,436
Provision for taxes on income 2,341 193 3 34 16 (87) (874) 9 1,635
Net Earnings 5,152 855 12 134 81 (300) 874 (7) 6,801
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date

-- 19 of 21 --

Year to Date
Innovative Medicine
Nine Months
September 27,
2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related
Nine Months
September 27,
2026
Non-GAAP
Cost of products sold 13,172	$ (2,289) (21) 10,862
Selling, marketing and admin expenses 9,083 9,083
Research and development expense 9,576 9,576
Other segment items 104 75 (274) (153) 286 38
Adjusted Income Before Tax by Segment 16,632 2,289 (75) - 274 174 (286) - - 19,008
MedTech
Nine Months
September 27,
2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related
Nine Months
September 27,
2026
Non-GAAP
Cost of products sold 11,035	$ (1,443) (55) (9) 9,528
Selling, marketing and admin expenses 8,989 (55) 8,934
Research and development expense 2,256 (7) 2,249
Other segment items 732 139 (375) (204) 31 (24) (675) (376)
Adjusted Income Before Tax by Segment 3,192 1,443 (139) 375 259 (31) 24 746 - 5,869
Expenses not allocated to segments
Nine Months
September 27,
2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related
Nine Months
September 27,
2026
Non-GAAP
Cost of products sold 47	$ 47
Selling, marketing and admin expenses 679 679
Research and development expense - -
Other segment items 6,327 (6,330) 1 (2)
Adjusted Income Before Tax by Segment (7,053) - 6,330 - - (1) - - - (724)
Johnson & Johnson Consolidated
Nine Months
September 27,
2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related
Nine Months
September 27,
2026
Non-GAAP
Cost of products sold 24,254	$ (3,732) (55) (21) (9) 20,437
Selling, marketing and admin expenses 18,751 (55) 18,696
Research and development expense 11,832 (7) 11,825
Other (Income) / Expense 6,405 (6,116) (231) (121) 262 (675) (476)
In-process research and development impairments 375 (375) -
Interest (Income)/Expense 136 136
Restructuring 247 (247) -
Adjusted Income Before Tax 12,771 3,732 6,116 375 533 142 (262) 746 - 24,153
Provision for taxes on income 1,792 718 1,361 93 161 63 (63) 136 (142) 4,119
Net Earnings 10,979 3,014 4,755 282 372 79 (199) 610 142 20,034
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

-- 20 of 21 --

Year to Date
Innovative Medicine
Nine Months
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Nine Months
Sept 28, 2025
Non-GAAP
Cost of products sold 11,670	$ (2,002) (24) 9,644
Selling, marketing and admin expenses 7,919 7,919
Research and development expense 8,361 8,361
Other segment items (520) 74 (275) 164 (14) (571)
Adjusted Income Before Tax by Segment 17,208 2,002 (74) - 299 (164) - 14 19,285
MedTech
Nine Months
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Nine Months
Sept 28, 2025
Non-GAAP
Cost of products sold 10,576	$ (1,433) (35) (52) 9,056
Selling, marketing and admin expenses 8,319 8,319
Research and development expense 2,052 37 2,089
Other segment items 132 (78) (267) (155) 163 (15) (220)
Adjusted Income Before Tax by Segment 3,912 1,433 78 302 170 (163) - 15 5,747
Expenses not allocated to segments
Nine Months
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Nine Months
Sept 28, 2025
Non-GAAP
Cost of products sold 42	$ 42
Selling, marketing and admin expenses 685 685
Research and development expense -
Other segment items (7,222) 6,898 (6) (330)
Adjusted Income Before Tax by Segment 6,495 - (6,898) - 6 - - - (397)
Johnson & Johnson Consolidated
Nine Months
Sept 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Nine Months
Sept 28, 2025
Non-GAAP
Cost of products sold 22,288	$ (3,435) (35) (76) 18,742
Selling, marketing and admin expenses 16,923 16,923
Research and development expense 10,413 37 10,450
Other (Income) / Expense (7,692) 6,894 (123) (436) 327 (29) (1,059)
In-process research and development impairments - -
Interest (Income)/Expense (62) (62)
Restructuring 144 (144) -
Adjusted Income Before Tax 27,615 3,435 (6,894) 302 475 (327) - 29 24,635
Provision for taxes on income 5,927 603 (1,541) 58 118 (73) (672) 9 4,429
Net Earnings 21,688 2,832 (5,353) 244 357 (254) 672 20 20,206
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

-- 21 of 21 --